Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell

Key Points

• Wall Street Zen upgraded Oculis from “strong sell” to “sell,” while the broader analyst consensus remains “Moderate Buy,” with nine Buy ratings and one Sell rating.
• Analysts have broadly reduced their price targets, bringing the average target to $38.33 versus Oculis’s recent share price of $12.68; the stock has declined substantially from its 52-week high of $34.47.
• Oculis reported a quarterly loss of $0.20 per share on just $0.38 million in revenue, and analysts expect a full-year loss of approximately $2.22 per share. Institutional investors own 22.3% of the clinical-stage ophthalmic drug developer.

Oculis (NASDAQ:OCS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday.

A number of other analysts have also issued reports on the stock. Stifel Nicolaus cut their price target on shares of Oculis from $50.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, June 1st. JPMorgan Chase & Co. lowered their price objective on shares of Oculis from $42.00 to $23.00 and set an "overweight" rating for the company in a research note on Wednesday, June 3rd. Guggenheim dropped their price objective on shares of Oculis from $75.00 to $45.00 and set a "buy" rating for the company in a report on Monday, June 1st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oculis in a research note on Friday, July 17th. Finally, Robert W. Baird reduced their target price on shares of Oculis from $49.00 to $38.00 and set an "outperform" rating on the stock in a report on Monday, June 1st. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Oculis currently has a consensus rating of "Moderate Buy" and an average price target of $38.33.

Oculis Stock Up 2.4%

NASDAQ:OCS opened at $12.68 on Friday. Oculis has a 52 week low of $10.52 and a 52 week high of $34.47. The stock's fifty day moving average is $12.17 and its two-hundred day moving average is $22.31. The stock has a market capitalization of $735.19 million, a price-to-earnings ratio of -7.29 and a beta of 0.51. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.20) earnings per share for the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 45.58%. The firm had revenue of $0.38 million during the quarter. Research analysts anticipate that Oculis will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Oculis

Several hedge funds and other institutional investors have recently made changes to their positions in OCS. Bank of America Corp DE grew its position in shares of Oculis by 9.1% during the first quarter. Bank of America Corp DE now owns 69,764 shares of the company's stock worth $1,855,000 after buying an additional 5,813 shares in the last quarter. Himension Capital Singapore PTE. LTD. acquired a new position in Oculis during the 1st quarter worth approximately $503,000. Koshinski Asset Management Inc. purchased a new stake in shares of Oculis in the 1st quarter valued at approximately $238,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Oculis in the 1st quarter valued at approximately $776,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Oculis in the 4th quarter valued at $9,862,000. Hedge funds and other institutional investors own 22.30% of the company's stock.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source